The three strains contained in the vaccine are recent and are of European origin. The real novelty of Gripovac®3 is the H1N2 strain which has been found in several European countries at a variable rate of prevalence: 89% of positive farms in Belgium, 54% in France, 48% in Spain and 41% in the Netherlands.
Influenza viruses are the major pathogens involved in acute respiratory disorders, and hyperthermia in sows can cause serious reproductive problems, including abortions. Economic losses incurred by swine influenza are estimated at €28 per sow per year. Gripovac®3 has demonstrated broad cross- protection against influenza strains present in Europe. The outstanding safety of Gripovac®3 means that the vaccine can be used at all stages of production of sows and gilts, and also fatteners. The vaccination schedule for sows consists of two 2-ml injections at a 3-week interval for the primary vaccination, and a booster at each gestation or subsequent lactations. If the booster is done 2 weeks prior to farrowing, piglets will be protected via colostral immunity.
Gripovac®3 received its full European centralised product licence on 14th January 2010 and will be distributed in all countries of the EMEA region in 25 or 50-dose bottles according to the country. Progressively it will replace Merial’s current swine influenza vaccine GRIPOVAC® which contains only H3N2 and H1N1 subtypes.
New Extension Swine Specialist Brings Experience and Enthusiasm to Iowa Pork Industry Center Position21-Dec-2017 1 years 1 months ago
This area is not intended to be a place to consult authors about their articles, but rather a place for open discussion among pig333.com users.